INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Dec 09, 2020 |
Director
Trans History: 742
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 2,439 | -- | 237,088 |
| Feb 23, 2021 |
Director
Trans History: 742
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 1,921 | $52.03 | 239,009 |
| Dec 13, 2013 |
Director, President & CEO
Trans History: 404
|
Director, President & CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 239,063 | -- | 239,063 |
| Dec 14, 2012 |
Director, EVP CSO Pres Regen Res Labs
Trans History: 617
|
Director, EVP CSO Pres Regen Res Labs | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 239,063 | -- | 239,063 |
| Dec 24, 2012 |
Director, President & CEO
Trans History: 404
|
Director, President & CEO | Form 4 | Bona fide gift | 59,271 | -- | 242,087 |
| Dec 16, 2011 |
Director, EVP CSO President Regeneron Re
Trans History: 617
|
Director, EVP CSO President Regeneron Re | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 150,000 | -- | 244,048 |
| Dec 14, 2017 |
Director, President and CSO
Trans History: 617
|
Director, President and CSO | Form 4 | Bona fide gift | 89,264 | -- | 244,670 |
| Dec 14, 2012 |
Director, EVP CSO Pres Regen Res Labs
Trans History: 617
|
Director, EVP CSO Pres Regen Res Labs | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 150,000 | -- | 245,295 |
| May 10, 2005 |
Director
Trans History: 742
|
Director | Form 4 | Other acquisition or disposition | -- | -- | 245,682 |
| Jan 14, 2005 |
Director
Trans History: 742
|
Director | Form 5 | Other acquisition or disposition | -- | -- | 245,682 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.